Modified Live Vaccine Tutorial

Learn how to properly mix, store, handle and administer Modified Live Vaccine

Product Description

PYRAMID® 4 + PRESPONSE® SQ is a single-dose vaccine aiding in the prevention of disease caused by bovine herpesvirus type 1 (IBR), parainfluenzavirus type 3 (PI3), bovine viral diarrhoea virus (BVDV), bovine respiratory syncytial virus (BRSV) and Mannheimia haemolytica. PYRAMID® 4 + PRESPONSE® SQ delivers enhanced efficacy with the help of the MetaStim adjuvant system, enhancing the animal’s response to the vaccine for greater protection.

Features and Benefits

  • Single-dose1,2 protection against BVD, IBR, PI3, BRSV and Mannheimia haemolytica
  • Dual phase metabolizable stimulant
    (MetaStim™)3,4,5,6
    • Enhances specific antibody response
    • Enhances cell-mediated immunity
  • Demonstrated cross-protection against virulent BVD-2 challenge7
  • Demonstrated foetal protection against BVD-1 infection8
  • Independent trials show:
    • Significant protection against M.haemolytica-induced pneumonic lung lesions9
    • Protection of young colostrum deprived calves from virulent M.haemolytica challenge10

Dosage Information

  • Inject 2 ml subcutaneously or intramuscularly on the side of the neck
  • Annual revaccination required
  • See product information sheet for more complete information

Safety Information

  • A small percentage of animals may show transient mild injection site swelling.
  • Do not vaccinate within 21 days before slaughter.
  • Burn container and all unused contents.
  • Should an allergic reaction occur for any reason, intramuscular adrenaline should be administered.
  • Store in the dark at 2 - 8°C. Avoid freezing.
  • Do not use in pregnant cows or in calves nursing pregnant cows
  • Each darkly colored rectangle represents an interaction between an antibody and the tested virus strain.

  • A high occurrence of interaction indicates a broad range of antigen/antibody interaction for the tested virus strain.

  • Using the two BVD strains in PYRAMID, this panel demonstrated a wide range of reactive proteins covered by the vaccine — 80 percent of the antibodies reacted.

Mode of action of the dual phase metabolizable stimulant (MetaStim™)

References:
1. Index of Veterinary Specialities. October-December 2013. Volume 51. Number 4. South African Publication.
2. Data on File. Ingelheim Pharmaceuticals (Pty) Ltd, Animal Health Division.
3. Cox JC, Coulter AR. Adjuvants – a classification and review of their modes of action. Vac 1997; 15(3):248-256.
4. Hjorth RN, Bonde GM, Piner ED, et al. The effect of Syntex adjuvant formulation (SAF-m) on humoral immunity to the influenza virus in the mouse. Vac 1997; 15(5):541-546.
5. Raychaudhuri S, Tonks M, Carbone F, et al. Induction of antigen-specific class I-restricted cyctoxic T cells by soluble proteins in vivo. Proc Natl Acad Sci USA 1992; 89:8308-8312.
6. Allison AC. Squalene and squalane emulsions as adjuvants. Methods 1999; 19:87-93.
7. Fairbanks K, Schnackel J, Chase CCL. Evaluation of a modified live virus Type-1a bovine viral diarrhea virus vaccine (Singer strain) against a Type-2 (strain 980) challenge. Vet Therap 2003; 4(1):24-31.
8. Schnackel JA, van Campen H, van Olphen A. Modified-live bovine viral diarrhea virus (BVDV) Type 1a vaccine provides protection against fetal infection after challenge with either Type 1a or Type 2 BVDV. Bov Prac 2007; 41:1-9.
9. Confer AW, Ayalew S, Panciera RJ, et al. Immunogenicity of recombinant Mannheimia haemolytica serotype 1 outer membrane protein PlpE and augmentation of a commercial vaccine. Vac 2003; 21:2821-2829.
10. Hodgins DC, Shewen PE. Vaccination of neonatal colostrum-deprived calves against Pastuerella haemolytica A1.Can J Vet Res 2000; 64:3-8.

Product Information Sheet